Back to top

Analyst Blog

Oncology and X-Ray products company, Varian Medical Systems (VAR - Analyst Report) has won the U.S. Food and Drug Administration (FDA) 510(k) clearance for its Vitesse software. The tool is intended for providing high-dose-rate (HDR) brachytherapy therapy for prostrate cancer treatment, using real-time ultrasound guidance.

This advanced version of Vitesse lowers the complexities of planning and performing the treatment, as well as reduces the time required, thereby enhancing operating room efficiency. Additionally, the device from the larger Oncology Systems has also received the CE Mark approval.

Varian is a leading manufacturer of integrated radiotherapy systems for cancer treatment, and a premier supplier of X-ray tubes for diagnostic imaging applications. The company operates in a technology-driven environment where success depends on the use of new technology, product development and upgrades. In the radiation oncology market, Varian competes with Accuray (ARAY - Analyst Report).

The company is poised to increase its market share in radiation oncology. It currently enjoys a healthy demand for its coveted TrueBeam technology, which has meaningfully contributed to its net order oncology growth.

Revenues from Oncology Systems increased 8% year over year to $524.3 million in the first quarter of fiscal 2013. Following the green signal from the FDA, the Vitesse program should further boost growth in the segment.

Moreover, Varian continues to post decent results despite the contagion of economic problems in Europe and sustained softness in certain end markets. It enjoys a strong balance sheet marked by low debt and sizeable cash. The company also periodically deploys capital to boost investor confidence via share repurchases.

However, Varian competes with larger players in a technology-intensive industry. Further, uncertainties stemming from health care reform and a still weak hospital capital spending environment across many developed countries, especially in Europe, are matters of concern.

The stock carries a Zacks Rank #3, which translates into a short-term Hold rating. Cantel Medical Corp. and Cyberonics Inc. (CYBX - Analyst Report) with Zacks Rank #1 (Strong Buy) are expected to do well in the medical instruments industry.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CTPARTNERS… CTP 13.33 +3.49%
SAIA INC SAIA 45.65 +1.00%
VASCO DATA… VDSI 13.57 +0.67%
AMEDISYS IN… AMED 20.18 +0.10%
FIRSTSERVIC… FSRV 55.66 -0.13%